FDAnews
www.fdanews.com/articles/114117-pfizer-to-pay-billions-for-alleged-off-label-promotions

Pfizer to Pay Billions for Alleged Off-Label Promotions

January 28, 2009
Pfizer had a $2.3 billion expense in its fourth quarter for settling allegations that it promoted off-label use of its Cox-2 inhibitor pain drug Bextra — just a few months after it recorded a $900 million cost related to Cox-2 product liability litigation. The $2.3 billion pretax and after-tax charge results from an agreement in principle to settle with Michael Sullivan, U.S. attorney for the District of Massachusetts, the Bextra (valdecoxib) allegations and “other open investigations,” the company says in its year-end statement.
Drug Industry Daily